Understanding and treating minimal residual disease defined by ctDNA. Independent education for patients, caregivers, and advocates, written by oncologists and patient advocates.
Why colorectal cancer can come back after surgery, and how a blood test can find cancer cells long before a scan can.
Start here →Which ctDNA assays are available, how to get one ordered, and how to make sense of a positive or negative result.
Testing guide →12 studies are currently enrolling patients with ctDNA-positive MRD. Status is refreshed from ClinicalTrials.gov.
Browse trials →This is a Phase II trial to study whether the combination of botensilimab and balstilimab, followed by balstilimab alone, is an effective treatment for CRC patients with MRD after standard treatment with surgery and chemotherapy or total neoadjuvant therapy.
This is a study to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after their treatment.
This is a study to assess the effects of the drugs Regorafenib and Lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy.
One email when something new is posted: a new clinical trial, meeting highlights, or educational material. No spam, unsubscribe any time.
